Non Muscle Invasive Bladder Cancer Clinical Trial
Official title:
A Phase 1/1b Study Evaluating the Safety, Pharmacology, and Clinical Effect of ZH9 Treatment in Patients With Non-Muscle Invasive Bladder Cancer
This is a first-in-human, multicenter, Phase 1/1b, 3-part, double-blind study of ZH9 in patients with recurrent NMIBC who are eligible for intravesical therapy. In Part 1, the safety, tolerability, and pharmacology of ZH9 IVI will be evaluated in a single ascending dose (SAD) patient cohort. In Part 2, the safety, tolerability, and pharmacology of ZH9 oral prime followed by ZH9 IVI will be evaluated in 2 patient cohorts at the doses and schedule established in Part 1. In Part 3, the safety, pharmacology, and clinical efficacy of ZH9 will be further evaluated in 2 expansion cohorts of patients with recurrent intermediate- and high-risk NMIBC.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT06020807 -
Analytical Specificity of Bladder EpiCheck Test in Healthy Population and Urology Patients Without Prior History or Evidence of Bladder Cancer
|
||
| Recruiting |
NCT06167356 -
Study on the Occurrence of Possible Relapses and on the Quality of Life in Patients Who Underwent TURBK.
|
||
| Withdrawn |
NCT01799499 -
A Prospective Open Label Comparative Dose Ranging Study Evaluating the Effect of Pre-TURBT Intravesical Instillation of Mitomycin C (MMC) Mixed With TC-3 Gel in Patients With Non Muscle Invasive Bladder Cancer (NMIBC)
|
N/A | |
| Completed |
NCT02343614 -
Celecoxib for the Treatment of Non-muscle Invasive Bladder Cancer
|
Phase 2 | |
| Recruiting |
NCT05945108 -
Brazilian Reality of Urinary Bladder Cancers - BRA-BLADDER
|
||
| Recruiting |
NCT06287541 -
The Necessity of a Second Transurethral Resection in High-risk Non-muscle-invasive Bladder Cancer Patients With Negative Urine Biomarker After Initial Transurethral Resection
|
N/A | |
| Terminated |
NCT02982395 -
Study to Evaluate the Efficacy and Safety Of Intravesical Nanoxel®M In BCG Refractory NMIBC
|
Phase 3 | |
| Completed |
NCT06205277 -
Predictors of Residual Tumor at Second Transurethral Resection for pT1 Non-muscle Invasive Bladder Cancer
|
||
| Completed |
NCT01731652 -
Study With TMX-101 in Patients With Carcinoma In Situ (CIS) Bladder Cancer
|
Phase 2 | |
| Recruiting |
NCT03421236 -
Intravesical Ty21a for the Treatment of Patients With Non-muscle-invasive Bladder Cancer (NMIBC)
|
Phase 1 | |
| Active, not recruiting |
NCT04387461 -
Study of CG0070 Given in Combination With Pembrolizumab, in Non-Muscle Invasive Bladder Cancer, Unresponsive to Bacillus Calmette-Guerin
|
Phase 2 | |
| Recruiting |
NCT06111235 -
A Study of Adjuvant Cretostimogene Grenadenorepvec for Treatment of Intermediate Risk NMIBC Following TURBT
|
Phase 3 | |
| Recruiting |
NCT02895620 -
Effect on Xpert® Bladder Test of Urines Inflammatory Milieu Induced by BCG Treatment of Patients With NMIBC
|
N/A | |
| Completed |
NCT01004211 -
Prospective Randomized Comparison of Transurethral Resection by Mean of White Light and Narrow Band Imaging
|
N/A | |
| Active, not recruiting |
NCT05981131 -
Follow up of Intravesical N-803 Plus BCG in BCG-Naive Non-Muscle Invasive Bladder Cancer (NMIBC)
|